Welcome to our dedicated page for Treatment.com AI news (Ticker: TREIF), a resource for investors and traders seeking the latest updates and insights on Treatment.com AI stock.
The TREIF news page aggregates coverage related to Rocket Doctor AI Inc., a healthcare technology company focused on physician-built, AI-powered digital health platforms. Here you can follow announcements about Rocket Doctor AI’s virtual care programs, payer relationships, technology developments, and market activities connected to its AI-driven clinical decision support and digital marketplace.
Rocket Doctor AI’s news frequently highlights the role of its Global Library of Medicine (GLM), a clinically validated decision support system, and its AI-powered platform operated through Rocket Doctor Inc. Updates often describe how over 300 medical doctors have used the platform to deliver hundreds of thousands of virtual or hybrid patient visits, supported by proprietary software, large language models, and connected medical devices.
Investors and observers can expect news items on topics such as virtual care initiatives in Canada and the United States, programs aimed at underserved, rural, and remote communities, and arrangements that support patients on Medicaid and Medicare. Releases also cover partnerships with pharmacies, community organizations, and health systems that integrate Rocket Doctor’s virtual care tools into local settings.
Because Rocket Doctor AI operates within digital health and AI in healthcare, company news often touches on the expansion of virtual care offerings, integration of diagnostic devices, and efforts to reduce administrative burdens for clinicians. This page provides a centralized view of these developments, allowing readers to track how the company’s AI-powered technology and marketplace are being applied across different regions and care settings. Bookmark this page to review new Rocket Doctor AI Inc. (TREIF) news as it becomes available on Stock Titan.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) endorses recent recommendations from a Washington roundtable on AI in healthcare. The company's AI-powered Global Library of Medicine (GLM) aims to address key challenges in healthcare, including:
- Alleviating workforce burdens
- Improving efficiency and patient outcomes
- Ensuring equitable access for patients and care teams
The GLM provides high-level clinical support to healthcare professionals, enhancing diagnostic accuracy and transparency. It operates in a secure environment, allowing Large Language Models to query trusted content, reducing risks of misdiagnosis and bias. The platform aims to streamline tasks for healthcare professionals, potentially impacting costs and efficiency for healthcare organizations.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has announced a new AI Pharmacy Assistant solution, set to launch in 2024. This tool aims to support pharmacists in their expanding role in healthcare, particularly in providing clinical decision support services. The AI Pharmacy Assistant is powered by Treatment's proprietary Global Library of Medicine (GLM), offering features such as:
- Automated patient history and symptom recording
- Documentation of patient interactions
- Enhanced diagnostic support
- Error minimization and increased clinical efficiency
- Comprehensive diagnostic information backed by up-to-date medical research
The global clinical decision support systems market is projected to grow from $2.46 billion in 2024 to $4.05 billion by 2029. This new product line represents an additional revenue stream for Treatment.com AI's GLM platform.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has announced a new AI Pharmacy Assistant solution, set to launch in 2024. This tool aims to support pharmacists in their expanding role within healthcare systems globally. The AI assistant, powered by Treatment's proprietary Global Library of Medicine (GLM), will help pharmacists by:
- Reducing time for patient history and symptom collection
- Automatically documenting patient interactions
- Extending diagnostic support capabilities
- Minimizing errors and increasing clinical efficiency
- Providing up-to-date medical research
The global clinical decision support systems market is projected to grow from $2.46 billion in 2024 to $4.05 billion by 2029. Treatment.com AI's CEO, Dr. Essam Hamza, emphasizes the product's potential to improve efficiency for payers, support pharmacists, and enhance patient care access.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has provided an update on the exercising of warrants issued upon conversion of special warrants on June 21, 2024. Nearly 800,000 warrants have been exercised, raising gross proceeds of approximately half a million dollars. The remaining warrants could potentially bring in over $2 million in additional funds.
CEO Dr. Essam Hamza highlighted that this cash injection will help expedite the company's plans, including the launch of 'AI Patient' and 'AI Doctor in the Pocket' products this fall. Treatment.com AI has also mentioned a strong acquisition pipeline under review, which could accelerate their growth strategy.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has provided an update on the exercising of warrants issued upon conversion of special warrants on June 21, 2024. Nearly 800,000 warrants have been exercised, raising gross proceeds of approximately half a million dollars. The remaining warrants could potentially bring in over $2 million in additional funds.
CEO Dr. Essam Hamza highlighted that this cash injection will enable the company to expedite its plans, including the launch of 'AI Patient' and 'AI Doctor in the Pocket' products this fall. Treatment.com AI also has a strong acquisition pipeline under review, which could accelerate their growth strategy. The company's core product is the Global Library of Medicine (GLM), an AI-driven healthcare engine providing clinical information with >92% accuracy on first diagnosis.
Treatment AI has provided a corporate update outlining significant progress and milestones. Financially, the company completed an oversubscribed private placement, raising $2.91M, and settled $1.1M in debt, becoming debt-free. New partnerships with aiXplain and Novus Health aim to enhance the Global Library of Medicine (GLM) and develop new healthcare solutions. A trial demonstrated GLM’s high diagnostic accuracy with a 92% success rate. The company expanded its executive team with Richard Atkins as COO and Dr. Jean Challiner as Executive Advisor, enhancing expertise in digital health and clinical decision support. Additionally, two new AI-driven SaaS solutions, AI Patient and AI Doctor in Your Pocket, are set for release in H2 2024.
Treatment AI has announced several significant updates. Financially, the company completed an oversubscribed private placement, raising $2.9 million, and settled over $1.1 million in debt, making it debt-free. They formed new partnerships with aiXplain and Novus Health to enhance their Global Library of Medicine (GLM) and explore new solutions. A recent trial showcased GLM's effectiveness, with a student achieving a 92% diagnostic accuracy rate. The company also bolstered its executive team with key appointments and plans to launch two new AI-driven solutions, AI Patient and AI Doctor in a Pocket, in the second half of 2024.
Treatment.com AI has signed a Collaborative Agreement with Novus Health to utilize its Global Library of Medicine (GLM) for enhancing Novus Health's Health Risk Assessment programs. Novus Health, serving over 1.5 million members, will leverage Treatment's AI-driven GLM to improve healthcare navigation and patient outcomes. This partnership aims to explore Health Risk Assessment and Medical Second Opinion opportunities, as well as develop new joint commercial applications. The collaboration intends to foster the development, validation, and commercialization of innovative solutions to improve healthcare efficiency and patient care outcomes.
Treatment.com AI Inc. appoints Richard Atkins as Chief Operating Officer, bringing over 30 years of experience in sales, partnerships, and executive management. Atkins will accelerate the company's expansion plans, emphasizing the importance of healthcare trust and reliability through AI-driven clinical insights. The company also extends marketing agreements and engages in advertising services to enhance its presence.
Treatment.com AI Inc. announces the contract renewal with a leading US medical school for utilizing their Medical Education Suite. The company is also in talks with various other medical and nursing schools. Treatment aims to reduce costs, streamline administrative work, and provide real-time case testing for schools. The company plans to launch two new subscription-based SaaS solutions in the second half of 2024. The Medical Education Suite is powered by Treatment's AI Global Library of Medicine, offering accurate clinical information and support.